


OvRSeq Analysis Report for TCGA-13-1403

2023-12-01


The vulnerability map indicate based on BRCAness probability and CYT to C1QA ratio (C2C) indications with a high vulnerability (score) for response to combination immunotherapy with PARPi and immune checkpoint inhibitors.



Patient values

Feature	Value
BRCAness status	0 (0.15)
Infiltration status	Desert
Molecular subtypes	MES
BRCAness immunotype	other
Vulnerability score	0.77
Immuno phenoscore	5
CYT to C1QA ratio (C2C)	0.69
Angiogenesis Score	1

Molecular markers and TCGA-OV Reference Values. Marker gene expression levels and respective Q1 and Q3 levels (interquartile range) from the TCGA cohort.



Feature	Patient Value	TCGA IQR
CD274	1.45	1.32 (0.87-1.86)
GZMB	2.27	2.55 (1.62-3.51)
PRF1	1.53	1.73 (1.15-2.50)
C1QA	5.66	7.35 (6.41-8.18)
CD8A	0.70	1.90 (1.17-2.65)
IDO1	5.06	4.16 (2.80-5.45)
FOXP3	1.20	1.94 (1.32-2.52)
TREM2	3.63	4.83 (3.76-5.64)
STAT1	6.89	7.01 (6.21-7.55)
HLA-DRA	6.56	7.26 (6.30-8.00)
CXCL10	4.52	6.38 (5.03-7.54)

Selected signatures/pathway scores (ssGSEA) normalized using min-max scaling with reference to TCGA values; and quantified immune cell infiltrates (quanTIseq).

